

## PATENT ASSIGNMENT

Electronic Version v1.1  
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT										
NATURE OF CONVEYANCE:	ASSIGNMENT										
CONVEYING PARTY DATA											
<table border="1"> <thead> <tr> <th>Name</th> <th>Execution Date</th> </tr> </thead> <tbody> <tr> <td>Enobia Canada Limited Partnership</td> <td>10/19/2012</td> </tr> </tbody> </table>		Name	Execution Date	Enobia Canada Limited Partnership	10/19/2012						
Name	Execution Date										
Enobia Canada Limited Partnership	10/19/2012										
RECEIVING PARTY DATA											
<table border="1"> <tr> <td>Name:</td> <td>Alexion Pharma International Sarl</td> </tr> <tr> <td>Street Address:</td> <td>Avenue du Tribunal-Federal 34</td> </tr> <tr> <td>City:</td> <td>Lausanne</td> </tr> <tr> <td>State/Country:</td> <td>SWITZERLAND</td> </tr> <tr> <td>Postal Code:</td> <td>1005</td> </tr> </table>		Name:	Alexion Pharma International Sarl	Street Address:	Avenue du Tribunal-Federal 34	City:	Lausanne	State/Country:	SWITZERLAND	Postal Code:	1005
Name:	Alexion Pharma International Sarl										
Street Address:	Avenue du Tribunal-Federal 34										
City:	Lausanne										
State/Country:	SWITZERLAND										
Postal Code:	1005										
PROPERTY NUMBERS Total: 3											
<table border="1"> <thead> <tr> <th>Property Type</th> <th>Number</th> </tr> </thead> <tbody> <tr> <td>Application Number:</td> <td>61329877</td> </tr> <tr> <td>Application Number:</td> <td>13695127</td> </tr> <tr> <td>PCT Number:</td> <td>CA1150258</td> </tr> </tbody> </table>		Property Type	Number	Application Number:	61329877	Application Number:	13695127	PCT Number:	CA1150258		
Property Type	Number										
Application Number:	61329877										
Application Number:	13695127										
PCT Number:	CA1150258										
CORRESPONDENCE DATA											
Fax Number:	6174287045										
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>											
Phone:	6174280200										
Email:	patentadministrator@clarkelbing.com										
Correspondent Name:	Kristina Bieker-Brady, Ph.D.										
Address Line 1:	Clark & Elbing LLP										
Address Line 2:	101 Federal Street										
Address Line 4:	Boston, MASSACHUSETTS 02110										
ATTORNEY DOCKET NUMBER:	50694-010001,002,W02										
NAME OF SUBMITTER:	/Kristina Bieker-Brady, Ph.D.										
<p>Total Attachments: 20          source=50694_010001_Executed_Assignment#page1.tif</p>											

CH \$120.00 61329877

source=50694\_010001\_Executed\_Assignment#page2.tif  
source=50694\_010001\_Executed\_Assignment#page3.tif  
source=50694\_010001\_Executed\_Assignment#page4.tif  
source=50694\_010001\_Executed\_Assignment#page5.tif  
source=50694\_010001\_Executed\_Assignment#page6.tif  
source=50694\_010001\_Executed\_Assignment#page7.tif  
source=50694\_010001\_Executed\_Assignment#page8.tif  
source=50694\_010001\_Executed\_Assignment#page9.tif  
source=50694\_010001\_Executed\_Assignment#page10.tif  
source=50694\_010001\_Executed\_Assignment#page11.tif  
source=50694\_010001\_Executed\_Assignment#page12.tif  
source=50694\_010001\_Executed\_Assignment#page13.tif  
source=50694\_010001\_Executed\_Assignment#page14.tif  
source=50694\_010001\_Executed\_Assignment#page15.tif  
source=50694\_010001\_Executed\_Assignment#page16.tif  
source=50694\_010001\_Executed\_Assignment#page17.tif  
source=50694\_010001\_Executed\_Assignment#page18.tif  
source=50694\_010001\_Executed\_Assignment#page19.tif  
source=50694\_010001\_Executed\_Assignment#page20.tif

I, Edith N. Huzar (name) a Notary Public residing at Branford, Connecticut USA  
\_\_\_\_\_ (place of residence) do hereby certify that Michael V. Greco (name  
of representative for Assignor) appeared before me and signed the foregoing document in my  
presence. I further certify that I have convinced myself by inspecting the relevant official  
documents that the said Michael V. Greco, President of Alexion Montreal Corp., Enobia  
Canada Limited Partnership, by its general partner Alexion Montreal Corp. (name and position  
of representative) has authority to sign as legal representative of Enobia Canada Limited  
Partnership (Assignor).

Seal

Signature by the notary

Edith N. Huzar

**EDITH N. HUZAR**  
**NOTARY PUBLIC**  
MY COMMISSION EXPIRES JULY 31, 2017

## ASSIGNMENT

For valuable consideration, we,

Full Name of Assignor	Jurisdiction of Incorporation/Creation	Business Address
Enobia Canada Limited Partnership	Ontario, Canada	2901 Rachel Street East, Suite 23 Montreal, Québec H1W 4A4 Canada

hereby assign to

Full Name of Assignee	Jurisdiction of Incorporation/Creation	Business Address
Alexion Pharma International Sàrl	Switzerland	Avenue du Tribunal-Fédéral 34 1005 Lausanne Switzerland

and to its successors and assigns (collectively hereinafter called "the Assignee"), our entire right, title, and interest throughout the world in the inventions and improvements which are subject of the below-identified patents and applications for a patent:

Title of Patent or Application for a Patent	Filing Date	Serial No. (Patent No.)	Jurisdiction
BONE DELIVERY COMPOSITIONS AND METHOD OF USING SAME TO TARGET PROTEINS TO BONE	April 21, 2004	60/563,828	United States
BONE DELIVERY CONJUGATES AND METHOD OF USING SAME TO TARGET PROTEINS TO BONE	July 23, 2004	60/590,347	United States
BONE DELIVERY CONJUGATES AND METHOD OF USING SAME TO TARGET PROTEINS TO BONE	October 4, 2004	60/614,984	United States
BONE DELIVERY CONJUGATES AND METHOD OF USING SAME TO TARGET PROTEINS TO BONE	April 21, 2005	PCT/CA2005/000615	Patent Cooperation Treaty
BONE DELIVERY CONJUGATES AND METHOD OF USING SAME TO TARGET PROTEINS TO BONE	April 21, 2005	11/111,664 (7,763,712)	United States
BONE DELIVERY CONJUGATES AND METHOD OF USING SAME TO TARGET PROTEINS TO BONE	December 15, 2009	12/638,527	United States
BONE DELIVERY CONJUGATES AND METHOD OF USING SAME TO TARGET PROTEINS TO BONE	June 3, 2010	12/793,517 (7,960,529)	United States
BONE DELIVERY CONJUGATES AND METHOD OF USING SAME TO TARGET PROTEINS TO BONE	April 21, 2005	2005235635 (2005235635)	Australia

Title of Patent or Application for a Patent	Filing Date	Serial No. (Patent No.)	Jurisdiction
BONE DELIVERY CONJUGATES AND METHOD OF USING SAME TO TARGET PROTEINS TO BONE	April 21, 2005	2,559,228	Canada
BONE DELIVERY CONJUGATES AND METHOD OF USING SAME TO TARGET PROTEINS TO BONE	April 21, 2005	05739065.0 (1759001)	Europe (validated in AT, BE, CH/LI, CZ, DE, DK, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SK, and TR)
BONE DELIVERY CONJUGATES AND METHOD OF USING SAME TO TARGET PROTEINS TO BONE	April 21, 2005	11000196.3	Europe
BONE DELIVERY CONJUGATES AND METHOD OF USING SAME TO TARGET PROTEINS TO BONE	April 21, 2005	11108510.1	Hong Kong
BONE DELIVERY CONJUGATES AND METHOD OF USING SAME TO TARGET PROTEINS TO BONE	April 21, 2005	2007-508698 (4874954)	Japan
BONE TARGETED TISSUE NON SPECIFIC ALKALINE PHOSPHATASE, KITS AND METHODS OF USE THEREOF	May 11, 2007	60/917,589	United States
BONE TARGETED ALKALINE PHOSPHATASE, KITS AND METHODS OF USE THEREOF	May 12, 2008	PCT/CA2008/000923	Patent Cooperation Treaty
BONE TARGETED ALKALINE PHOSPHATASE, KITS AND METHODS OF USE THEREOF	May 12, 2008 (international filing date); July 19, 2010 (371 (c) date)	12/599,679	United States
BONE TARGETED ALKALINE PHOSPHATASE, KITS AND METHODS OF USE THEREOF	May 12, 2008	2008250945	Australia
BONE TARGETED ALKALINE PHOSPHATASE, KITS AND METHODS OF USE THEREOF	May 12, 2008	PI0811198-7	Brazil
BONE TARGETED ALKALINE PHOSPHATASE, KITS AND METHODS OF USE THEREOF	May 12, 2008	2,687,001	Canada
BONE TARGETED ALKALINE PHOSPHATASE, KITS AND METHODS OF USE THEREOF	May 12, 2008	08757088.3 (2158319)	Europe (validated in AT, BE, CH/LI, CZ, DE, DK, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SK, and TR)

Title of Patent or Application for a Patent	Filing Date	Serial No. (Patent No.)	Jurisdiction
BONE TARGETED ALKALINE PHOSPHATASE, KITS AND METHODS OF USE THEREOF	May 12, 2008	11004496.3	Europe
BONE TARGETED ALKALINE PHOSPHATASE, KITS AND METHODS OF USE THEREOF	May 12, 2008 (international filing date); August 26, 2011 (actual filing date)	20 2008 018 131.3 [utility model application, registration no. 20 2008 018 131.3]	Germany
BONE TARGETED ALKALINE PHOSPHATASE, KITS AND METHODS OF USE THEREOF	May 12, 2008	10107384.7	Hong Kong
BONE TARGETED ALKALINE PHOSPHATASE, KITS AND METHODS OF USE THEREOF	May 12, 2008	12102957.3	Hong Kong
BONE TARGETED ALKALINE PHOSPHATASE, KITS AND METHODS OF USE THEREOF	May 12, 2008	202057	Israel
BONE TARGETED ALKALINE PHOSPHATASE, KITS AND METHODS OF USE THEREOF	May 12, 2008	2010-507770	Japan
METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF MATRIX MINERALIZATION DISORDERS	April 30, 2010	61/329,877	United States
METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF MATRIX MINERALIZATION DISORDERS	April 29, 2011	PCT/CA2011/050258	Patent Cooperation Treaty
COMPOSITIONS COMPRISING NATRIURETIC PEPTIDES AND METHODS OF USE THEREOF	December 27, 2010	61/427,365	United States
COMPOSITIONS COMPRISING NATRIURETIC PEPTIDES AND METHODS OF USE THEREOF	August 16, 2011	61/524,155	United States
COMPOSITIONS COMPRISING NATRIURETIC PEPTIDES AND METHODS OF USE THEREOF	December 23, 2011	PCT/CA2011/050807	Patent Cooperation Treaty
COMPOSITIONS COMPRISING NATRIURETIC PEPTIDES AND METHODS OF USE THEREOF	December 23, 2011	13/336,651	United States
COMPOSITIONS COMPRISING ALKALINE PHOSPHATASE AND/OR NATRIURETIC PEPTIDE AND METHODS OF USE THEREOF	October 19, 2011	61/549,047	United States

Title of Patent or Application for a Patent	Filing Date	Serial No. (Patent No.)	Jurisdiction
COMPOSITIONS COMPRISING ALKALINE PHOSPHATASE AND/OR NATRIURETIC PEPTIDE AND METHODS OF USE THEREOF	May 21, 2012	61/649,717	United States
COMPOSITIONS COMPRISING ALKALINE PHOSPHATASE AND/OR NATRIURETIC PEPTIDE AND METHODS OF USE THEREOF	May 22, 2012	PCT/US2012/039004	Patent Cooperation Treaty
COMPOSITION, METHODS AND REAGENTS FOR THE SYNTHESIS OF A SOLUBLE FORM OF HUMAN PEX	February 24, 1999	2,262,056	Canada
COMPOSITION, METHODS AND REAGENTS FOR THE SYNTHESIS OF A SOLUBLE FORM OF HUMAN PHEX	February 24, 2000	PCT/CA2000/000201	Patent Cooperation Treaty
COMPOSITION, METHODS AND REAGENTS FOR THE SYNTHESIS OF A SOLUBLE FORM OF HUMAN PHEX	February 24, 2000 (international filing date); August 21, 2001 (371 (c) date)	09/913,955 (6,790,649)	United States
COMPOSITION, METHODS AND REAGENTS FOR THE SYNTHESIS OF A SOLUBLE FORM OF HUMAN PHEX	June 8, 2004	10/862,459 (7,427,498)	United States
COMPOSITION, METHODS AND REAGENTS FOR THE SYNTHESIS OF A SOLUBLE FORM OF HUMAN PHEX	February 24, 2000	200027900 (776042)	Australia
COMPOSITION, METHODS AND REAGENTS FOR THE SYNTHESIS OF A SOLUBLE FORM OF HUMAN PHEX	February 24, 2000 (international filing date); October 25, 2004 (actual filing date)	2004222823 (2004222823)	Australia
COMPOSITION, METHODS AND REAGENTS FOR THE SYNTHESIS OF A SOLUBLE FORM OF HUMAN PHEX	February 24, 2000	2,365,094	Canada
COMPOSITION, METHODS AND REAGENTS FOR THE SYNTHESIS OF A SOLUBLE FORM OF HUMAN PHEX	February 24, 2000	00906114.4	Europe

Title of Patent or Application for a Patent	Filing Date	Serial No. (Patent No.)	Jurisdiction
COMPOSITION, METHODS AND REAGENTS FOR THE SYNTHESIS OF A SOLUBLE FORM OF HUMAN PHEX	February 24, 2000	2000-601144	Japan
METHOD AND COMPOSITIONS FOR PROMOTING OSTEOGENESIS	August 23, 2000	60/227,012	United States
METHOD AND COMPOSITIONS FOR PROMOTING OSTEOGENESIS	August 23, 2001	PCT/CA2001/001220	Patent Cooperation Treaty
METHOD AND COMPOSITIONS FOR PROMOTING OSTEOGENESIS	August 23, 2001 (international filing date); July 29, 2003 (371 (c) date)	10/362,259 (7,399,466)	United States
METHOD AND COMPOSITIONS FOR PROMOTING OSTEOGENESIS	August 23, 2001	2001287429 (2001287429)	Australia
METHOD AND COMPOSITIONS FOR PROMOTING OSTEOGENESIS	August 23, 2001	2,418,461	Canada
METHOD AND COMPOSITIONS FOR PROMOTING OSTEOGENESIS	August 23, 2001	01966885.4 (1311691)	Europe (validated in CH/LI, DE, FR, GB, and IT)
METHOD AND COMPOSITIONS FOR PROMOTING OSTEOGENESIS	August 23, 2001	2002-520839	Japan
DERIVATIVES OF SUCCINIC AND GLUTARIC ACIDS AND ANALOGS THEREOF USEFUL AS INHIBITORS OF PHEX	December 3, 2002	60/430,382	United States
DERIVATIVES OF SUCCINIC AND GLUTARIC ACIDS AND ANALOGS THEREOF USEFUL AS INHIBITORS OF PHEX	December 3, 2003	10/727,119 (7,105,539)	United States
DERIVATIVES OF SUCCINIC AND GLUTARIC ACIDS AND ANALOGS THEREOF USEFUL AS INHIBITORS OF PHEX	May 26, 2006	11/441,764 (7,365,091)	United States
DERIVATIVES OF SUCCINIC AND GLUTARIC ACIDS AND ANALOGS THEREOF USEFUL AS INHIBITORS OF PHEX	December 3, 2003	PCT/CA2003/001893	Patent Cooperation Treaty



Title of Patent or Application for a Patent	Filing Date	Serial No. (Patent No.)	Jurisdiction
DERIVATIVES OF SUCCINIC AND GLUTARIC ACIDS AND ANALOGS THEREOF USEFUL AS INHIBITORS OF PHEX	December 3, 2003 (international filing date); January 9, 2006 (371 (c) date)	10/537,146	United States
DERIVATIVES OF SUCCINIC AND GLUTARIC ACIDS AND ANALOGS THEREOF USEFUL AS INHIBITORS OF PHEX	December 3, 2003	2003291867	Australia
DERIVATIVES OF SUCCINIC AND GLUTARIC ACIDS AND ANALOGS THEREOF USEFUL AS INHIBITORS OF PHEX	December 3, 2003	03767325.8	Europe
METHOD OF USE OF SPECIFIC NATRIURETIC PEPTIDE RECEPTOR C LIGANDS, TRANSGENIC NON-HUMAN MAMMALS EXPRESSING SPECIFIC NATRIURETIC PEPTIDE RECEPTOR C ANTAGONISTS AND CELLS THEREOF	August 24, 2005	11/210,631 (7,470,668)	United States
MAMMALIAN BONE HORMONE PRECURSOR, NUCLEIC ACID SEQUENCE AND THERAPEUTIC USES THEREOF	December 20, 2001	60/341,224	United States
BONE POLYPEPTIDE-1	December 20, 2002	PCT/IB2002/005778	Patent Cooperation Treaty
BONE POLYPEPTIDE-1	December 20, 2002	10/327,514	United States
BONE POLYPEPTIDE-1	December 20, 2002 (international filing date); August 4, 2004 (371 (c) date)	10/499,762 (7,425,531)	United States
BONE POLYPEPTIDE-1	December 20, 2002	2002356392	Australia
BONE POLYPEPTIDE-1	December 20, 2002	2,469,972	Canada
BONE POLYPEPTIDE-1	December 20, 2002	02805460.9 (1458749)	Europe (validated in CH/LI, DE, FR, and GB)

Title of Patent or Application for a Patent	Filing Date	Serial No. (Patent No.)	Jurisdiction
NUCLEIC ACID MOLECULE, METHOD AND KIT FOR SELECTING A NUCLEIC ACID HAVING A DESIRED FEATURE	August 18, 2000	09/641,931 (6,830,885)	United States
NUCLEIC ACID MOLECULES, METHODS AND KITS FOR SELECTING A NUCLEIC ACID HAVING A DESIRED FEATURE	August 17, 2001	PCT/CA2001/001169	Patent Cooperation Treaty
NUCLEIC ACID MOLECULES, METHODS AND KITS FOR SELECTING A NUCLEIC ACID HAVING A DESIRED FEATURE	August 17, 2001	2001287396	Australia
NUCLEIC ACID MOLECULES, METHODS AND KITS FOR SELECTING A NUCLEIC ACID HAVING A DESIRED FEATURE	August 17, 2001	2,418,097	Canada
NUCLEIC ACID MOLECULES, METHODS AND KITS FOR SELECTING A NUCLEIC ACID HAVING A DESIRED FEATURE	August 17, 2001	01966851.6	Europe

This assignment includes said patents and applications for a patent, any and all United States and foreign patents, utility models, and design registrations granted for any of said inventions or improvements, and the right to claim priority based on the filing dates of said patents and applications for a patent under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other treaties of like purposes; and we authorize the Assignee to apply in all countries in our name or in its own name for patents, utility models, design registrations, and like rights of exclusion, and for inventors' certificates for said inventions and improvements; and we agree for ourselves and our respective heirs, legal representatives and assigns, without further compensation, to perform such lawful acts and to sign such further applications, assignments, Preliminary Statements, and other lawful documents as the Assignee may reasonably request to effectuate fully this assignment. This assignment also includes the right to sue for past acts of infringement, whether based on any patents listed herein, patents issuing from applications listed herein, or provisional rights from any applications for a patent listed herein.

IN WITNESS WHEREOF, I hereto set my hand and seal at Cheshire, CT,  
this 19th day of October, 2013.

Michael V. Greco L.S.  
**Michael V. Greco**  
President of Alexion Montreal Corp.  
Enobia Canada Limited Partnership, by its general partner Alexion Montreal Corp.

On this 19th day of October, 2013, before me, the undersigned notary public,  
personally appeared **Michael V. Greco**, proved to me through satisfactory evidence of identification,  
which consisted of Driver's license, to be the person whose name is subscribed  
to the foregoing Assignment, entitled to sign this Assignment on behalf of the Assignor, and  
acknowledged that he/she executed the same as his/her free act and deed for the purposes therein  
contained.

Edith N. Huzar  
Notary Public

My Commission Expires:

**EDITH N. HUZAR**  
**NOTARY PUBLIC**  
MY COMMISSION EXPIRES JULY 31, 2017

[Notary's Seal Here]

IN WITNESS WHEREOF, I hereto set my hand and seal at \_\_\_\_\_,  
this \_\_\_\_ day of \_\_\_\_\_, 20\_\_\_\_.

\_\_\_\_\_  
L.S.

**Stephen Blockley**  
General Manager  
Alexion Pharma International Sàrl

On this \_\_\_\_ day of \_\_\_\_\_, 20\_\_, before me, the undersigned notary public, personally appeared **Stephen Blockley**, proved to me through satisfactory evidence of identification, which consisted of \_\_\_\_\_, to be the person whose name is subscribed to the foregoing Assignment, entitled to sign this Assignment on behalf of the Assignee, and acknowledged that he/she executed the same as his/her free act and deed for the purposes therein contained.

\_\_\_\_\_  
Notary Public

My Commission Expires:

[Notary's Seal Here]

**ASSIGNMENT**

For valuable consideration, we,

Full Name of Assignor	Jurisdiction of Incorporation/Creation	Business Address
Enobia Canada Limited Partnership	Ontario, Canada	2901 Rachel Street East, Suite 23 Montreal, Québec H1W 4A4 Canada

hereby assign to

Full Name of Assignee	Jurisdiction of Incorporation/Creation	Business Address
Alexion Pharma International Sàrl	Switzerland	Avenue du Tribunal-Fédéral 34 1005 Lausanne Switzerland

and to its successors and assigns (collectively hereinafter called "the Assignee"), our entire right, title, and interest throughout the world in the inventions and improvements which are subject of the below-identified patents and applications for a patent:

Title of Patent or Application for a Patent	Filing Date	Serial No. (Patent No.)	Jurisdiction
BONE DELIVERY COMPOSITIONS AND METHOD OF USING SAME TO TARGET PROTEINS TO BONE	April 21, 2004	60/563,828	United States
BONE DELIVERY CONJUGATES AND METHOD OF USING SAME TO TARGET PROTEINS TO BONE	July 23, 2004	60/590,347	United States
BONE DELIVERY CONJUGATES AND METHOD OF USING SAME TO TARGET PROTEINS TO BONE	October 4, 2004	60/614,984	United States
BONE DELIVERY CONJUGATES AND METHOD OF USING SAME TO TARGET PROTEINS TO BONE	April 21, 2005	PCT/CA2005/000615	Patent Cooperation Treaty
BONE DELIVERY CONJUGATES AND METHOD OF USING SAME TO TARGET PROTEINS TO BONE	April 21, 2005	11/111,664 (7,763,712)	United States
BONE DELIVERY CONJUGATES AND METHOD OF USING SAME TO TARGET PROTEINS TO BONE	December 15, 2009	12/638,527	United States
BONE DELIVERY CONJUGATES AND METHOD OF USING SAME TO TARGET PROTEINS TO BONE	June 3, 2010	12/793,517 (7,960,529)	United States
BONE DELIVERY CONJUGATES AND METHOD OF USING SAME TO TARGET PROTEINS TO BONE	April 21, 2005	2005235635 (2005235635)	Australia



Title of Patent or Application for a Patent	Filing Date	Serial No. (Patent No.)	Jurisdiction
BONE DELIVERY CONJUGATES AND METHOD OF USING SAME TO TARGET PROTEINS TO BONE	April 21, 2005	2,559,228	Canada
BONE DELIVERY CONJUGATES AND METHOD OF USING SAME TO TARGET PROTEINS TO BONE	April 21, 2005	05739065.0 (1759001)	Europe (validated in AT, BE, CH/LI, CZ, DE, DK, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SK, and TR)
BONE DELIVERY CONJUGATES AND METHOD OF USING SAME TO TARGET PROTEINS TO BONE	April 21, 2005	11000196.3	Europe
BONE DELIVERY CONJUGATES AND METHOD OF USING SAME TO TARGET PROTEINS TO BONE	April 21, 2005	11108510.1	Hong Kong
BONE DELIVERY CONJUGATES AND METHOD OF USING SAME TO TARGET PROTEINS TO BONE	April 21, 2005	2007-508698 (4874954)	Japan
BONE TARGETED TISSUE NON SPECIFIC ALKALINE PHOSPHATASE, KITS AND METHODS OF USE THEREOF	May 11, 2007	60/917,589	United States
BONE TARGETED ALKALINE PHOSPHATASE, KITS AND METHODS OF USE THEREOF	May 12, 2008	PCT/CA2008/000923	Patent Cooperation Treaty
BONE TARGETED ALKALINE PHOSPHATASE, KITS AND METHODS OF USE THEREOF	May 12, 2008 (international filing date); July 19, 2010 (371 (c) date)	12/599,679	United States
BONE TARGETED ALKALINE PHOSPHATASE, KITS AND METHODS OF USE THEREOF	May 12, 2008	2008250945	Australia
BONE TARGETED ALKALINE PHOSPHATASE, KITS AND METHODS OF USE THEREOF	May 12, 2008	PI0811198-7	Brazil
BONE TARGETED ALKALINE PHOSPHATASE, KITS AND METHODS OF USE THEREOF	May 12, 2008	2,687,001	Canada
BONE TARGETED ALKALINE PHOSPHATASE, KITS AND METHODS OF USE THEREOF	May 12, 2008	08757088.3 (2158319)	Europe (validated in AT, BE, CH/LI, CZ, DE, DK, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SK, and TR)




Title of Patent or Application for a Patent	Filing Date	Serial No. (Patent No.)	Jurisdiction
BONE TARGETED ALKALINE PHOSPHATASE, KITS AND METHODS OF USE THEREOF	May 12, 2008	11004496.3	Europe
BONE TARGETED ALKALINE PHOSPHATASE, KITS AND METHODS OF USE THEREOF	May 12, 2008 (international filing date); August 26, 2011 (actual filing date)	20 2008 018 131.3 [utility model application, registration no. 20 2008 018 131.3]	Germany
BONE TARGETED ALKALINE PHOSPHATASE, KITS AND METHODS OF USE THEREOF	May 12, 2008	10107384.7	Hong Kong
BONE TARGETED ALKALINE PHOSPHATASE, KITS AND METHODS OF USE THEREOF	May 12, 2008	12102957.3	Hong Kong
BONE TARGETED ALKALINE PHOSPHATASE, KITS AND METHODS OF USE THEREOF	May 12, 2008	202057	Israel
BONE TARGETED ALKALINE PHOSPHATASE, KITS AND METHODS OF USE THEREOF	May 12, 2008	2010-507770	Japan
METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF MATRIX MINERALIZATION DISORDERS	April 30, 2010	61/329,877	United States
METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF MATRIX MINERALIZATION DISORDERS	April 29, 2011	PCT/CA2011/050258	Patent Cooperation Treaty
COMPOSITIONS COMPRISING NATRIURETIC PEPTIDES AND METHODS OF USE THEREOF	December 27, 2010	61/427,365	United States
COMPOSITIONS COMPRISING NATRIURETIC PEPTIDES AND METHODS OF USE THEREOF	August 16, 2011	61/524,155	United States
COMPOSITIONS COMPRISING NATRIURETIC PEPTIDES AND METHODS OF USE THEREOF	December 23, 2011	PCT/CA2011/050807	Patent Cooperation Treaty
COMPOSITIONS COMPRISING NATRIURETIC PEPTIDES AND METHODS OF USE THEREOF	December 23, 2011	13/336,651	United States
COMPOSITIONS COMPRISING ALKALINE PHOSPHATASE AND/OR NATRIURETIC PEPTIDE AND METHODS OF USE THEREOF	October 19, 2011	61/549,047	United States



Title of Patent or Application for a Patent	Filing Date	Serial No. (Patent No.)	Jurisdiction
COMPOSITIONS COMPRISING ALKALINE PHOSPHATASE AND/OR NATRIURETIC PEPTIDE AND METHODS OF USE THEREOF	May 21, 2012	61/649,717	United States
COMPOSITIONS COMPRISING ALKALINE PHOSPHATASE AND/OR NATRIURETIC PEPTIDE AND METHODS OF USE THEREOF	May 22, 2012	PCT/US2012/039004	Patent Cooperation Treaty
COMPOSITION, METHODS AND REAGENTS FOR THE SYNTHESIS OF A SOLUBLE FORM OF HUMAN PEX	February 24, 1999	2,262,056	Canada
COMPOSITION, METHODS AND REAGENTS FOR THE SYNTHESIS OF A SOLUBLE FORM OF HUMAN PHEX	February 24, 2000	PCT/CA2000/000201	Patent Cooperation Treaty
COMPOSITION, METHODS AND REAGENTS FOR THE SYNTHESIS OF A SOLUBLE FORM OF HUMAN PHEX	February 24, 2000 (international filing date); August 21, 2001 (371 (c) date)	09/913,955 (6,790,649)	United States
COMPOSITION, METHODS AND REAGENTS FOR THE SYNTHESIS OF A SOLUBLE FORM OF HUMAN PHEX	June 8, 2004	10/862,459 (7,427,498)	United States
COMPOSITION, METHODS AND REAGENTS FOR THE SYNTHESIS OF A SOLUBLE FORM OF HUMAN PHEX	February 24, 2000	200027900 (776042)	Australia
COMPOSITION, METHODS AND REAGENTS FOR THE SYNTHESIS OF A SOLUBLE FORM OF HUMAN PHEX	February 24, 2000 (international filing date); October 25, 2004 (actual filing date)	2004222823 (2004222823)	Australia
COMPOSITION, METHODS AND REAGENTS FOR THE SYNTHESIS OF A SOLUBLE FORM OF HUMAN PHEX	February 24, 2000	2,365,094	Canada
COMPOSITION, METHODS AND REAGENTS FOR THE SYNTHESIS OF A SOLUBLE FORM OF HUMAN PHEX	February 24, 2000	00906114.4	Europe





Title of Patent or Application for a Patent	Filing Date	Serial No. (Patent No.)	Jurisdiction
COMPOSITION, METHODS AND REAGENTS FOR THE SYNTHESIS OF A SOLUBLE FORM OF HUMAN PHEX	February 24, 2000	2000-601144	Japan
METHOD AND COMPOSITIONS FOR PROMOTING OSTEOGENESIS	August 23, 2000	60/227,012	United States
METHOD AND COMPOSITIONS FOR PROMOTING OSTEOGENESIS	August 23, 2001	PCT/CA2001/001220	Patent Cooperation Treaty
METHOD AND COMPOSITIONS FOR PROMOTING OSTEOGENESIS	August 23, 2001 (international filing date); July 29, 2003 (371 (c) date)	10/362,259 (7,399,466)	United States
METHOD AND COMPOSITIONS FOR PROMOTING OSTEOGENESIS	August 23, 2001	2001287429 (2001287429)	Australia
METHOD AND COMPOSITIONS FOR PROMOTING OSTEOGENESIS	August 23, 2001	2,418,461	Canada
METHOD AND COMPOSITIONS FOR PROMOTING OSTEOGENESIS	August 23, 2001	01966885.4 (1311691)	Europe (validated in CH/LI, DE, FR, GB, and IT)
METHOD AND COMPOSITIONS FOR PROMOTING OSTEOGENESIS	August 23, 2001	2002-520839	Japan
DERIVATIVES OF SUCCINIC AND GLUTARIC ACIDS AND ANALOGS THEREOF USEFUL AS INHIBITORS OF PHEX	December 3, 2002	60/430,382	United States
DERIVATIVES OF SUCCINIC AND GLUTARIC ACIDS AND ANALOGS THEREOF USEFUL AS INHIBITORS OF PHEX	December 3, 2003	10/727,119 (7,105,539)	United States
DERIVATIVES OF SUCCINIC AND GLUTARIC ACIDS AND ANALOGS THEREOF USEFUL AS INHIBITORS OF PHEX	May 26, 2006	11/441,764 (7,365,091)	United States
DERIVATIVES OF SUCCINIC AND GLUTARIC ACIDS AND ANALOGS THEREOF USEFUL AS INHIBITORS OF PHEX	December 3, 2003	PCT/CA2003/001893 -	Patent Cooperation Treaty



Title of Patent or Application for a Patent	Filing Date	Serial No. (Patent No.)	Jurisdiction
DERIVATIVES OF SUCCINIC AND GLUTARIC ACIDS AND ANALOGS THEREOF USEFUL AS INHIBITORS OF PHEX	December 3, 2003 (international filing date); January 9, 2006 (371 (c) date)	10/537,146	United States
DERIVATIVES OF SUCCINIC AND GLUTARIC ACIDS AND ANALOGS THEREOF USEFUL AS INHIBITORS OF PHEX	December 3, 2003	2003291867	Australia
DERIVATIVES OF SUCCINIC AND GLUTARIC ACIDS AND ANALOGS THEREOF USEFUL AS INHIBITORS OF PHEX	December 3, 2003	03767325.8	Europe
METHOD OF USE OF SPECIFIC NATRIURETIC PEPTIDE RECEPTOR C LIGANDS, TRANSGENIC NON-HUMAN MAMMALS EXPRESSING SPECIFIC NATRIURETIC PEPTIDE RECEPTOR C ANTAGONISTS AND CELLS THEREOF	August 24, 2005	11/210,631 (7,470,668)	United States
MAMMALIAN BONE HORMONE PRECURSOR, NUCLEIC ACID SEQUENCE AND THERAPEUTIC USES THEREOF	December 20, 2001	60/341,224	United States
BONE POLYPEPTIDE-1	December 20, 2002	PCT/IB2002/005778	Patent Cooperation Treaty
BONE POLYPEPTIDE-1	December 20, 2002	10/327,514	United States
BONE POLYPEPTIDE-1	December 20, 2002 (international filing date); August 4, 2004 (371 (c) date)	10/499,762 (7,425,531)	United States
BONE POLYPEPTIDE-1	December 20, 2002	2002356392	Australia
BONE POLYPEPTIDE-1	December 20, 2002	2,469,972	Canada
BONE POLYPEPTIDE-1	December 20, 2002	02805460.9 (1458749) -	Europe (validated in CH/LI, DE, FR, and GB)



Title of Patent or Application for a Patent	Filing Date	Serial No. (Patent No.)	Jurisdiction
NUCLEIC ACID MOLECULE, METHOD AND KIT FOR SELECTING A NUCLEIC ACID HAVING A DESIRED FEATURE	August 18, 2000	09/641,931 (6,830,885)	United States
NUCLEIC ACID MOLECULES, METHODS AND KITS FOR SELECTING A NUCLEIC ACID HAVING A DESIRED FEATURE	August 17, 2001	PCT/CA2001/001169	Patent Cooperation Treaty
NUCLEIC ACID MOLECULES, METHODS AND KITS FOR SELECTING A NUCLEIC ACID HAVING A DESIRED FEATURE	August 17, 2001	2001287396	Australia
NUCLEIC ACID MOLECULES, METHODS AND KITS FOR SELECTING A NUCLEIC ACID HAVING A DESIRED FEATURE	August 17, 2001	2,418,097	Canada
NUCLEIC ACID MOLECULES, METHODS AND KITS FOR SELECTING A NUCLEIC ACID HAVING A DESIRED FEATURE	August 17, 2001	01966851.6	Europe

This assignment includes said patents and applications for a patent, any and all United States and foreign patents, utility models, and design registrations granted for any of said inventions or improvements, and the right to claim priority based on the filing dates of said patents and applications for a patent under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other treaties of like purposes; and we authorize the Assignee to apply in all countries in our name or in its own name for patents, utility models, design registrations, and like rights of exclusion, and for inventors' certificates for said inventions and improvements; and we agree for ourselves and our respective heirs, legal representatives and assigns, without further compensation, to perform such lawful acts and to sign such further applications, assignments, Preliminary Statements, and other lawful documents as the Assignee may reasonably request to effectuate fully this assignment. This assignment also includes the right to sue for past acts of infringement, whether based on any patents listed herein, patents issuing from applications listed herein, or provisional rights from any applications for a patent listed herein.



IN WITNESS WHEREOF, I hereto set my hand and seal at \_\_\_\_\_,  
this \_\_\_\_ day of \_\_\_\_\_, 20\_\_.

\_\_\_\_\_  
L.S.

**Michael V. Greco**

President of Alexion Montreal Corp.

Enobia Canada Limited Partnership, by its general partner Alexion Montreal Corp.

On this \_\_\_\_ day of \_\_\_\_\_, 20\_\_, before me, the undersigned notary public, personally appeared **Michael V. Greco**, proved to me through satisfactory evidence of identification, which consisted of \_\_\_\_\_, to be the person whose name is subscribed to the foregoing Assignment, entitled to sign this Assignment on behalf of the Assignor, and acknowledged that he/she executed the same as his/her free act and deed for the purposes therein contained.

\_\_\_\_\_  
Notary Public

My Commission Expires:

[Notary's Seal Here]



IN WITNESS WHEREOF, I hereto set my hand and seal at Lausanne - (Canton de Vaud),  
this 24<sup>th</sup> day of July, 2012.

[Signature] L.S.  
**Stephen Blockley**  
General Manager  
Alexion Pharma International Sàrl

On this \_\_\_\_ day of \_\_\_\_\_, 20\_\_, before me, the undersigned notary public, personally appeared **Stephen Blockley**, proved to me through satisfactory evidence of identification, which consisted of \_\_\_\_\_, to be the person whose name is subscribed to the foregoing Assignment, entitled to sign this Assignment on behalf of the Assignee, and acknowledged that he/she executed the same as his/her free act and deed for the purposes therein contained.

\_\_\_\_\_  
Notary Public

My Commission Expires:

[Notary's Seal Here]



Legalization number 191.- \_\_\_\_\_

On the basis of a specimen laid down in my office, I the undersigned Damien VENTURA, Notary public in Lausanne for the State of Canton de Vaud, Switzerland, certify the authenticity of the signature laid on the other side by Mr Stephen Blockley, from Näfels, Glarus-Nord (Glaris, Switzerland), in Prangins (Vaud, Switzerland), who validly commit "Alexion Pharma International Sàrl (Alexion Pharma International GmbH) (Alexion Pharma International LLC)", in Lausanne (Vaud, Switzerland), by his own signature. \_\_\_\_\_

Lausanne, Canton de Vaud, Switzerland, the thirtieth day of July two thousand twelve. —




[Signature]

**Act in patent number 81.- Vidimus**

I, the undersigned Damien VENTURA, Notary public in Lausanne for the State of Canton de Vaud, Switzerland, certify that the present copy of the document called "**Assignment**", dated of the twenty-fourth day of July two thousand and twelve, is a true and correct copy of the original, which was produced to him and that the photograph is a true likeness of the individual concerned.

Lausanne, Canton de Vaud, Switzerland, the thirty-first day of July two thousand and twelve (DONT ACTE, délivré en brevet, à Lausanne, le trente et un juillet deux mille douze.)



*D. Ventura*

